Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has earned a consensus recommendation of “Buy” from the eight ratings firms that are covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $23.02.
Several research firms have weighed in on ZYNE. BidaskClub downgraded Zynerba Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, May 29th. Canaccord Genuity began coverage on Zynerba Pharmaceuticals in a research note on Monday, April 22nd. They issued a “buy” rating and a $8.09 price target for the company. LADENBURG THALM/SH SH restated a “buy” rating and issued a $26.00 price target on shares of Zynerba Pharmaceuticals in a research note on Thursday,